Cyclic Ether Pyrazolopyrimidine PDE2 Inhibitors for CSF Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current phosphodiesterase 2 (PDE2) inhibitors lack selectivity, high plasma protein binding, low cerebrospinal fluid (CSF) to plasma ratio, and inadequate tissue permeability, which limits their efficacy in treating central nervous system diseases.
Innovation Solution
Development of cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide compounds with high selectivity towards PDE2, low plasma protein binding, high CSF to plasma ratio, and good membrane permeability, and metabolic stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PDE2 inhibitors are used, then PDE2 inhibition is achieved, but selectivity is poor and plasma protein binding is high
Solution Approach 1:
The patent modifies chemical parameters of PDE2 inhibitors by introducing specific cyclic ether derivatives at the R2 position and adjusting substituent patterns on the pyrazolo[1,5-a]pyrimidine core. These parameter changes result in compounds with reduced plasma protein binding (e.g., compound 1 shows 94.7% unbound fraction in human plasma) while maintaining PDE2 inhibition efficacy.
2Reliability
If current PDE2 inhibitors are used, then PDE2 inhibition is achieved, but CSF to plasma ratio is low
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by designing compounds with specific molecular properties (molecular weight, lipophilicity, hydrogen bond donors/acceptors). The cyclic ether derivatives at R2 position improve blood-brain barrier penetration, achieving high CSF to plasma ratios (e.g., compound 1 achieves 0.79 CSF/plasma ratio at 10 µg/kg dose in rats).
3Reliability
If current PDE2 inhibitors are used, then PDE2 inhibition is achieved, but tissue permeability is inadequate
Solution Approach 1:
The patent modifies structural parameters to enhance membrane permeability, including introducing cyclic ether groups (tetrahydrofuran, dioxane, oxetane) at the R2 position and optimizing aromatic substituent patterns. These changes improve lipophilicity and molecular flexibility, enabling better tissue penetration while maintaining PDE2 inhibition.
4Reliability
If higher dosages are used to achieve therapeutic effect, then PDE2 inhibition is improved, but side effects increase
Solution Approach 1:
The patent extracts and eliminates the problematic high plasma protein binding property from conventional PDE2 inhibitors by replacing them with cyclic ether derivative compounds. This extraction of the harmful binding characteristic allows therapeutic effects to be achieved at lower dosages (e.g., 10-50 mg/kg oral dose in preclinical models) with reduced side effect profile.
Data Source
AI summary
The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of formula (I)wherein R1, R2, R3, R5, R6 and A are as defined herein. The compounds of formula (1) are inhibitors of phosphodiesterase 2 and useful in treating central nervous system diseases and other diseases. The invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.